Tuning Reactivity of Platinum(II) Complexes

Tuning Reactivity of Platinum(II) Complexes Tuning Reactivity of Platinum(II) Complexes

pfeiffer.nele60
from pfeiffer.nele60 More from this publisher
29.07.2013 Views

the hydrolysis of the complex, whereas the non-hydrolysable and sterically demanding lipophilic chelating amine (dach) ligand makes the complex less polar. This has been proposed to contribute to a better cellular uptake. 60 In addition, the dach ligand prevents the binding of the DNA repair proteins by pointing into the major DNA groove (Figure 1.6). These adducts shield the inhibition of DNA replication, resulting in apoptosis and cell death. Oxaliplatin and carboplatin both have bidentate leaving groups that reduce the severity of the side effects by slow ligand exchange reaction with plasma proteins. Figure 1.6: DNA adducts formed by oxaliplatin 13 . Sterically Hindered Platinum(II) Complex (ZD0473) One of the main mechanisms of cisplatin-resistance is an increase in intracellular thiol- mediated detoxification by peptides and proteins such as glutathione and metallothionines (see section 1.3.2.5). Cis-ammninedichlorido(2-methylpyridine)Pt(II), (ZD0473) (Figure 1.7) is the first drug to be administered orally. It is sterically hindered platinum(II) complex and is in phase II clinical trials. 61 Crystal structures of the complex have shown that the pyridine ring is tilted at 102.7° with respect to the PtN2Cl2 coordination square-plane. 62 This introduces steric hindrance directly above the platinum coordination plane, limiting the axial attack by the incoming nucleophile to 11

one side of the coordination square-plane. 63 In addition; this steric hindrance makes it less susceptible to deactivation by the S-containing proteins than cisplatin. This is essential in retarding in vivo cellular detoxification reaction by ubiquitous deactivating scavengers like GSH and MT. This feature is also linked to its ability to overcome cisplatin/drug resistance mechanisms. H 3 N N ZD0473 Figure 1.7: Structure of a sterically hindered platinum(II) complex (ZD0473) that circumvents cisplatin resistance. 1.3.3.2 Platinum(IV) Complexes Platinum(II)-based complexes: cisplatin, carboplatin and oxaliplatin are associated with poor saline solubility, high reactivity and therefore, poor bioavailability and lower pharmaco-stability. In addition, these drugs can only be administered intravenously, making them expensive. An oral drug must be neutral, lipophylic, water soluble and stable to survive in the gastrointestinal media. 64 As a result, octahedral Pt(IV) complexes were developed. Notable examples are satraplatin (JM216) (see Figure 1.2), which has entered phase III of clinical trials for the treatment of ovarian and small lung cancers; and LA-12. These complexes display greater advantages that include 12 Pt i. Greater stability to ligand substitution reactions and bioreductive activation which allows a greater proportion of the drug to arrive at its target the DNA. 65 ii. Higher solubility in aqueous solution enables them to be administered orally. iii. Moderate lipophilic properties due to the presence of bulky non-leaving groups enable them to circumvent resistance caused by decreased Pt accumulation. iv. Exhibition of lower nephrotoxicity and neurotoxicity, besides better sensitivity in cisplatin resistant cell-lines than cisplatin. Cl Cl

the hydrolysis <strong>of</strong> the complex, whereas the non-hydrolysable and sterically demanding<br />

lipophilic chelating amine (dach) ligand makes the complex less polar. This has been<br />

proposed to contribute to a better cellular uptake. 60 In addition, the dach ligand<br />

prevents the binding <strong>of</strong> the DNA repair proteins by pointing into the major DNA groove<br />

(Figure 1.6). These adducts shield the inhibition <strong>of</strong> DNA replication, resulting in<br />

apoptosis and cell death. Oxaliplatin and carboplatin both have bidentate leaving groups<br />

that reduce the severity <strong>of</strong> the side effects by slow ligand exchange reaction with plasma<br />

proteins.<br />

Figure 1.6: DNA adducts formed by oxaliplatin 13 .<br />

Sterically Hindered <strong>Platinum</strong>(<strong>II</strong>) Complex (ZD0473)<br />

One <strong>of</strong> the main mechanisms <strong>of</strong> cisplatin-resistance is an increase in intracellular thiol-<br />

mediated detoxification by peptides and proteins such as glutathione and<br />

metallothionines (see section 1.3.2.5). Cis-ammninedichlorido(2-methylpyridine)Pt(<strong>II</strong>),<br />

(ZD0473) (Figure 1.7) is the first drug to be administered orally. It is sterically hindered<br />

platinum(<strong>II</strong>) complex and is in phase <strong>II</strong> clinical trials. 61 Crystal structures <strong>of</strong> the complex<br />

have shown that the pyridine ring is tilted at 102.7° with respect to the PtN2Cl2<br />

coordination square-plane. 62 This introduces steric hindrance directly above the<br />

platinum coordination plane, limiting the axial attack by the incoming nucleophile to<br />

11

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!